Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader-Reference-Cited by-同舟云学术

Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader

Published:2022-09-29 Issue:10 Volume:13 Page:1621-1627
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Divakaran Anand¹^ORCID,Scholtz Cole R.²,Zahid Huda²^ORCID,Lin Wenwei³,Griffith Elizabeth C.³,Lee Richard E.³^ORCID,Chen Taosheng³^ORCID,Harki Daniel A.¹²^ORCID,Pomerantz William C. K.¹²^ORCID

Affiliation:

1. Department of Medicinal Chemistry, University of Minnesota, 2231 Sixth Street SE, Minneapolis, Minnesota 55455, United States

2. Department of Chemistry, University of Minnesota, 207 Pleasant Street SE, Minneapolis, Minnesota 55455, United States

3. Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, United States

Funder

National Center for Advancing Translational Sciences

University of Minnesota

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00300

Reference42 articles.

1. Bromodomains as therapeutic targets

2. The dTAG system for immediate and target-specific protein degradation

3. Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition

4. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

5. Targeting MYC dependence in cancer by inhibiting BET bromodomains

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Degraders in epigenetic therapy: PROTACs and beyond;Theranostics;2024

2. Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations;ACS Omega;2023-09-06

3. Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity;Journal of Medicinal Chemistry;2023-06-08

4. Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes;ACS Chemical Biology;2023-06-01

5. Recent progress and structural analyses of domain‐selective BET inhibitors;Medicinal Research Reviews;2023-03-27